Hls Therapeutics Stock Gross Profit
| HLS Stock | CAD 3.50 0.09 2.64% |
HLS Therapeutics fundamentals help investors to digest information that contributes to HLS Therapeutics' financial success or failures. It also enables traders to predict the movement of HLS Stock. The fundamental analysis module provides a way to measure HLS Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HLS Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Gross Profit | 55.5 M | 58.2 M | |
| Gross Profit Margin | 0.88 | 0.92 |
HLS | Gross Profit |
HLS Therapeutics Company Gross Profit Analysis
HLS Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current HLS Therapeutics Gross Profit | 50.76 M |
Most of HLS Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HLS Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
HLS Gross Profit Driver Correlations
Understanding the fundamental principles of building solid financial models for HLS Therapeutics is extremely important. It helps to project a fair market value of HLS Stock properly, considering its historical fundamentals such as Gross Profit. Since HLS Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of HLS Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of HLS Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, HLS Therapeutics reported 50.76 M of gross profit. This is 97.74% lower than that of the Pharmaceuticals sector and 98.35% lower than that of the Health Care industry. The gross profit for all Canada stocks is 99.81% higher than that of the company.
HLS Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of HLS Therapeutics from analyzing HLS Therapeutics' financial statements. These drivers represent accounts that assess HLS Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of HLS Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 557.2M | 439.1M | 371.4M | 235.1M | 123.9M | 70.9M | |
| Enterprise Value | 603.3M | 525.6M | 447.8M | 311.8M | 189.6M | 199.0M |
HLS Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0274 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | 181.96 M | ||||
| Shares Outstanding | 31.79 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 65.10 % | ||||
| Number Of Shares Shorted | 4.64 K | ||||
| Price To Book | 0.96 X | ||||
| Price To Sales | 1.93 X | ||||
| Revenue | 63.07 M | ||||
| Gross Profit | 50.76 M | ||||
| EBITDA | 21.94 M | ||||
| Net Income | (27.53 M) | ||||
| Cash And Equivalents | 20.72 M | ||||
| Cash Per Share | 1.70 X | ||||
| Total Debt | 87.62 M | ||||
| Debt To Equity | 50.50 % | ||||
| Current Ratio | 1.70 X | ||||
| Book Value Per Share | 2.50 X | ||||
| Cash Flow From Operations | 15.79 M | ||||
| Short Ratio | 0.14 X | ||||
| Earnings Per Share | (0.98) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 91 | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 109.69 M | ||||
| Total Asset | 209.06 M | ||||
| Retained Earnings | (175.46 M) | ||||
| Working Capital | 17.41 M | ||||
| Net Asset | 209.06 M | ||||
| Last Dividend Paid | 0.076 |
About HLS Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HLS Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HLS Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HLS Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with HLS Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.